MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of convertible...
$194,000K
Proceeds from issuance of
common stock-Equity...
$94,000K
Proceeds from senior
secured term loan, net of...
$73,500K
Proceeds from issuance of
common stock-At Market...
$71,532K
Proceeds from issuance of
common stock under...
$592K
Proceeds from sales and
maturities of investments
$108,133K
Proceeds from exercise of
stock options
$367K
Net cash provided by
financing activities
$433,479K
Net cash provided by
(used in) investing...
$31,611K
Canceled cashflow
$512K
Canceled cashflow
$76,522K
Net increase
(decrease) in cash and cash...
$389,583K
Canceled cashflow
$75,507K
Payments of debt issuance
costs
$474K
Payments of other
offering costs for the atm...
$38K
Stock-based compensation
expense
$9,195K
Non-cash interest
expense on royalty...
$6,263K
Accounts payable
$1,795K
Non-cash lease expense
$264K
Non-cash interest
expense on senior...
$34K
Depreciation expense
$6K
Purchases of investments
$76,520K
Purchases of property and
equipment
$2K
Net cash used in
operating activities
-$75,196K
Effect of exchange rate
changes on cash and cash...
-$311K
Canceled cashflow
$17,557K
Net loss
-$80,987K
Prepaid expenses and
other assets
$6,482K
Accrued expenses
-$4,963K
Operating lease
liabilities
-$211K
Net amortization of
premiums and accretion of...
-$110K
Research and development
expenses-Obexelimab-Single Reportable...
$31,760K
Research and development
expenses-Single Reportable...
$14,914K
General and
administrative-Single Reportable...
$10,812K
Research and development
expenses-Orelabrutinib-Single Reportable...
$10,101K
Stock-based
compensation-Single Reportable...
$9,195K
Other segment
items-Single Reportable...
$3,637K
Research and development
expenses-Other Programs...
$568K
Back
Back
Cash Flow
source: myfinsight.com
Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma, Inc. (ZBIO)